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Pathological cardiac hypertrophy involves auto/paracrinemediators acting throughGq/11-coupled receptors.
A novel signaling route stimulated by bg-subunits of Gq/11 results in the autophosphorylation of ERK1/2 on
a new site and the nuclear retention of ERK1/2, thereby activating hypertrophic gene programs.Myocardial hypertrophy is an adapta-
tional response of the heart to increased
work load that involves enhanced protein
synthesis and an increase in size of indi-
vidual cardiomyocytes. However, under
pathological conditions such as hyperten-
sion or after myocardial infarction malad-
aptive cardiac hypertrophy can result in
tissue fibrosis and is associated with a
high risk of mortality due to heart failure
and arrhythmia (Hill and Olson, 2008).
Multiple growth factor receptors and their
downstream signaling pathways—in-
cluding the activation of Ras and Rho
GTPases, various mitogen-activated pro-
tein kinase (MAPK) cascades, and amulti-
tude of calcium-dependent regulators
such as calcineurin, CaM-kinases, and
the transcription factor NFAT—have been
all implicated in cardiac hypertrophy
(Clerk and Sugden, 2000; Heineke and
Molkentin, 2006; Hill and Olson, 2008).
Accumulating evidence indicates that
the initial phase in the development of
maladaptive myocardial hypertrophy
involves the production of cardiac para-
and/or autocrine factors like endothelin-1,
norepinephrine, and angiotensin II, all of
which act on cognate receptors ex-
pressed in the myocardium (Clerk and
Sugden, 2000; Heineke and Molkentin,
2006; Hill and Olson, 2008). These recep-
tors belong to the large family of cell
surface molecules that initiate signal
transmission by stimulating heterotri-
meric G proteins of the Gq/11, G12/13, and
Gi/o families. Aligned with these observa-
tions, the cardiomyocyte-specific trans-
genic overexpression of some of these G
protein-coupled receptors (GPCRs),
such as a1-adrenergic and angiotensin(AT1) receptors, or activated mutants of
their coupled G protein a-subunits, Gaq,
results in myocardial hypertrophy (Dorn
and Brown, 1999). Furthermore, mice
lacking both Gaq and Ga11 in cardiomyo-
cytes are protected from cardiac hyper-
trophy in response to pressure overload
(Wettschureck et al., 2001). Taken to-
gether, these findings suggest that chronic
activation of Gq and G11 and their down-
stream signaling pathways is necessary
and sufficient for myocardial hypertrophy.
However, the nature of the molecular
mechanisms deployed by these heterotri-
meric G proteins and their coupled recep-
tors to initiate a hypertrophic response in
the myocardium are still not fully under-
stood (Figure 1).
In this regard, a recent study by Lorenz
and colleagues (2009), provided evidence
that this process involves a novel
signaling route initiated by Gq/11. Here,
ERK1/2 autophosphorylation on a previ-
ously undescribed site, threonine 188
(Thr188), results in the translocation of
ERK1/2 to the nucleus and the persistent
activation of ERK1/2-dependent nuclear
events that contribute to cardiac hyper-
trophy. At the molecular level, Lorenz
et al. (2009) showed that GPCRs coupled
to Gq/11 cause the activation and Thr188
phosphorylation of ERK1/2 by a two-
pronged mechanism. Upon agonist acti-
vation of Gq-coupled receptors, the Gaq
subunit stimulates the Raf1/MEK/ERK1/2
pathway, reflected by the accumulation of
ERK1/2 phosphorylated in the ThrGluTyr
(TEY) motif within its activation loop
(Turjanski et al., 2007 and references
therein). Concomitantly, the bg subunits
released from Gq/11 associate with theDevelopmental Cell 16,Raf1/MEK/ERK1/2 complex, enhancing
the efficiency of ERK1/2 activation and
favoring the intermolecular autophos-
phorylation of ERK1/2 on its Thr188 (Lor-
enz et al., 2009). The presence of Thr188
phosphorylated ERK1/2 was detected in
experimental animal models of cardiac
hypertrophy, and readily observed in
failing, hypertrophic human hearts, sup-
porting the clinical relevance of these
findings.
In contrast to the phosphorylation of the
TEY motif, phosphorylation of Thr188 was
not required for ERK1/2 activation but led
to prolonged nuclear retention, thus
enhancing its ability to phosphorylate its
nuclear targets involved in the initiation of
a hypertrophic gene program. Indeed,
elegant studies involving the transgenic
expression of mutant forms of ERK2
showed that mice expressing a ‘‘phos-
phorylation mimic’’ Thr188Asp mutant
are more sensitive to the development of
cardiac hypertrophy and fibrosis in
response to pressure overload caused
by transverse aortic constriction (Lorenz
et al., 2009). In contrast, mice expressing
a nonphosphorylatable Thr188Ala mutant
were partially protected from pressure-
induced cardiac hypertrophy. Surpris-
ingly, substitution of Thr188 for Ser had
a similar mild protective effect, suggesting
that Thr and Ser are not interchangeable
and that perhaps Ser may not represent
an effective substrate for intermolecular
phosphorylationonERK1/2.Overall, these
studies provide additional mechanistic
insight and support the relevance of the
novel Gq/11-ERK1/2 pathway in pressure-
overload-inducedmyocardial hypertrophy
in vivo.February 17, 2009 ª2009 Elsevier Inc. 163
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PreviewsFigure 1. Signalling Pathways Linking Gq/11-Coupled Receptors with the Induction of
Cardiac Hypertrophy Gene Expression Programs
Activation of cardiac Gq/11-coupled receptors plays a central role in maladaptive cardiac hypertrophy.
Shown are the major signaling pathways believed to mediate this effect including the recently described
Gbg-dependent autophosphorylation of ERK1/2 at Thr188 which promotes nuclear retention of ERK1/2
resulting in the induction of the hypertrophy-specific gene program.With respect to the signal specificity of
these events, Lorenz et al. observed that
Gbg dimers released from Gq can cause
ERK Thr188 phosphorylation, while Gbg
dimers released fromGi could not, in spite
of stimulating ERK1/2 activation effec-
tively. It is conceivable that different
Gbg dimers may exert distinct functions
or that pathways mediated by different
G-proteins are compartmentalized; how-
ever, it is also plausible that the activation
ofGq/11a-subunits and theirdiversedown-
stream targets may dictate the specificity
of Gbg function. For example, Gaq/11-
initiated pathways may control the access
of Gbg to the Raf1/MEK/ERK1/2 complex,
or regulate the subcellular distribution and
function of the multitude of scaffolding
molecules, kinases, and phosphatases
that regulate the ERK1/2 MAPK cascade164 Developmental Cell 16, February 17, 20(Turjanski et al., 2007). Indeed, other
Gq/11 targets, such as RhoA, phospholi-
pase C-b, phospholipase C-3, and the
JNK, p38, and ERK5 MAPK cascades
can all regulate gene expression in cardio-
myocytes and contribute to cardiac
hypertrophy (Clerk and Sugden, 2000;
Frey and Olson, 2003; Heineke and Mol-
kentin, 2006; Hill and Olson, 2008). These
changes in gene expression may serve as
a prerequisite for Gbg-dependent ERK1/2
Thr188 phosphorylation. They may also
function in parallel to it. Although the
Raf1/MEK/ERK1/2 cascadeplaysaprom-
inent role in cardiac hypertrophy, its acti-
vation may not always be strictly required
(Heineke and Molkentin, 2006; Lorenz
et al., 2009, and references therein).
Thus, in addition to enabling ERK1/2
Thr188phosphorylation, theaberrant acti-09 ª2009 Elsevier Inc.vation of Gq/11-regulated pathways, if
persistent, may circumvent the strict
requirement of ERK1/2 stimulation to
mount a cardiac hypertrophic response.
It will therefore be interesting to explore
whether manipulation of the complex
interplay among these diverse signaling
events downstream of Gq/11 will offer
novel targets for pharmacological inter-
vention to prevent heart failure, one of
the leading causes of death in developed
countries.
It is worth noting that ERK1/2 phospho-
Thr188 may also contribute to the activa-
tion of growth promoting and transforming
pathways initiated by Gq/11 in other
contexts (Dorsam and Gutkind, 2007). In
addition, polypeptide growth factors
acting on tyrosine kinase receptors ap-
pear to stimulate this novel Gq/11-ERK1/2
pathwaybya still incompletely understood
mechanism (Lorenz et al., 2009). Further
study of these intriguing possibilities will
certainly represent an exciting area for
future exploration.
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